UBS Group Initiates Coverage on Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Alnylam Pharmaceuticals (NASDAQ:ALNY) Coverage Initiated by Analysts at UBS Group

UBS Group assumed coverage on shares of Alnylam Pharmaceuticals in a research report on Thursday. They issued a "buy" rating and a $354.00 price objective for the company.

Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Rated “Buy” in New Coverage at UBS Group

UBS Group assumed coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) in a note issued to investors on Thursday. The firm set a “buy” rating and a $354.00 price target on the biopharmaceutical company’s stock. UBS Group’s target price would indicate a potential upside of 51.59% from the stock’s previous close. A […]